89 related articles for article (PubMed ID: 21137237)
1. [Risk factors for hematologic toxicity and multifaceted analysis of blood in Hodgkin's disease: a model for hematologic toxicity].
Datsenko PV; Podol'skiĭ PN; Pan'shin GA; Sotnikov VM; Bozhenko VK
Vopr Onkol; 2010; 56(5):571-5. PubMed ID: 21137237
[TBL] [Abstract][Full Text] [Related]
2. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
3. [Five-year outcome of a new combination chemotherapy with CEA/ABVD for advanced Hodgkin's disease with poor prognosis].
Kharchenko VP; Datsenko PV; Panyshin GA; Sotnikov VM; Mel'nik IuD
Vopr Onkol; 2006; 52(5):531-7. PubMed ID: 17168361
[TBL] [Abstract][Full Text] [Related]
4. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
5. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
[TBL] [Abstract][Full Text] [Related]
6. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
Busia A; Laffranchi A; Viviani S; Bonfante V; Villani F
Anticancer Res; 2010 Oct; 30(10):4381-7. PubMed ID: 21036768
[TBL] [Abstract][Full Text] [Related]
7. Pohl-Pinkus constrictions of hair following chemotherapy for Hodgkin's disease.
Williamson PJ; de Berker D
Br J Haematol; 2005 Mar; 128(5):582. PubMed ID: 15725077
[No Abstract] [Full Text] [Related]
8. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
9. Acute promyelocytic leukemia following ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy for Hodgkin's disease.
Amadori S; Papa G; Anselmo AP; Fidani P; Mandelli F; Biagini C
Cancer Treat Rep; 1983 Jun; 67(6):603-4. PubMed ID: 6190561
[No Abstract] [Full Text] [Related]
10. Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).
Lipton JH; Gospodarowicz M; Reingold S
Hematol Oncol; 1996 Mar; 14(1):29-31. PubMed ID: 8613133
[TBL] [Abstract][Full Text] [Related]
11. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
Brusamolino E; Lunghi F; Orlandi E; Astori C; Passamonti F; Baraté C; Pagnucco G; Baio A; Franchini P; Lazzarino M; Bernasconi C
Haematologica; 2000 Oct; 85(10):1032-9. PubMed ID: 11025593
[TBL] [Abstract][Full Text] [Related]
12. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
13. [Results of the treatment of Hodgkin's disease stage III and IV using the ABVD and BACOP programs].
Leszko B; Słomkowski M; Przybyszewska M; Apel D; Pawelski S
Acta Haematol Pol; 1986; 17(3-4):81-90. PubMed ID: 2438894
[No Abstract] [Full Text] [Related]
14. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin PJ; Lowry L; Horwich A; Jack A; Mead B; Hancock BW; Smith P; Qian W; Patrick P; Popova B; Pettitt A; Cunningham D; Pettengell R; Sweetenham J; Linch D; Johnson PW
J Clin Oncol; 2009 Nov; 27(32):5390-6. PubMed ID: 19738111
[TBL] [Abstract][Full Text] [Related]
15. Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.
Suzuki T; Takeuchi M; Saeki H; Yamazaki S; Koga H; Abe D; Nishimura M; Nakaseko C; Nakasa H; Nakamura H; Ariyoshi N; Kitada M
Clin Ther; 2010 Mar; 32(3):527-31. PubMed ID: 20399989
[TBL] [Abstract][Full Text] [Related]
16. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
[TBL] [Abstract][Full Text] [Related]
17. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP.
Anselmo AP; Cartoni C; Bellantuono P; Maurizi-Enrici R; Aboulkair N; Ermini M
Haematologica; 1990; 75(2):155-8. PubMed ID: 1694156
[TBL] [Abstract][Full Text] [Related]
18. Second hematologic malignancies after ABVD: Two case reports and a retrospective study of 183 Hodgkin lymphoma patients.
Leong C; Ngeow J; Tan I; Quek R; Tao M; Loh Y; Tan HC; Lim ST
Acta Oncol; 2010; 49(2):257-9. PubMed ID: 19839917
[No Abstract] [Full Text] [Related]
19. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
Arakelyan N; Jais JP; Delwail V; Brière J; Moles-Moreau MP; Sénécal D; Berthou C; Desablens B; Colonna P; Andrieu JM;
Cancer; 2010 Sep; 116(17):4054-62. PubMed ID: 20564152
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement.
Lagrange JL; Thyss A; Caldani C; Héry M; Schneider M; Bensadoun JR
Bull Cancer; 1988; 75(8):801-6. PubMed ID: 2460169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
